Oruka Therapeutics, Inc. ORKA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s accrued expenses?
- Oruka Therapeutics, Inc. (ORKA) reported accrued expenses of $9.29M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Oruka Therapeutics, Inc.'s accrued expenses increased by 64.0% year-over-year, from $5.66M to $9.29M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s accrued expenses has grown at a 67.0% compound annual growth rate (CAGR), from $815K to $10.59M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.